Motley FoolAUG 143 min read$PIII

P3 Health (PIII) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool.Thursday, Aug. 14, 2025 at 4:30 p.m. ETChief Executive Officer - Aric CoffmanContinue reading ...

Original reporting

Motley Fool · Motley Fool Transcribing

Published Aug 14, 2025, 9:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 15, 2025, 12:32 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

P3 Health (PIII) Q2 2025 Earnings Call Transcript — source image — Source · www.fool.com

Decision brief

The 30-second read

$PIIINeutralLow

Why it matters

The transcript indicates stability, with no immediate red flags or major catalysts, suggesting limited short-term trading opportunities.

Market read

The news has low immediate trading relevance but offers a snapshot of the company's current financial state.

What to watch

Potential upcoming product launches or regulatory changes not discussed in the transcript could influence future performance.

Timing: Long-term

Background

P3 Health's Q2 2025 earnings call provides insights into its financial health amid ongoing industry developments.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PIIINeutralMedium confidence

Context

Primary focus of the earnings call transcript; relevant for assessing company-specific developments.

Expected impact

Likely minimal short-term price movement; potential for slight upward drift if positive sentiment persists.

Evidence & confidence

The transcript reflects steady performance without major catalysts, but positive sentiment could support minor gains.

Market effects

Sector

Limited; the focus remains on healthcare and life sciences sectors with no immediate sector-wide shifts.

Regional

Minimal; no regional economic changes indicated.

Global

Negligible; the news pertains to a specific company's quarterly results.

Counterpoint

What could challenge this read

The neutral tone suggests limited upside; some investors may prefer to wait for more definitive catalysts before acting.

Key entities

Executive
Aric Coffman
Chief Executive Officer of P3 Health.

Read at source ← All news

AUG 17

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.

fool.com7 min

AUG 11

$PIIIHighAI 9/10

P3 Health Partners Swings To Q2 Profit, Lifts 2026 Guidance; Stock Up

P3 Health Partners (PIII) reported Q2 2026 revenue of $386.4 million, up 9% from $355.8 million a year earlier, and swung to net income of $15.7 million versus a $43.7 million loss. Adjusted EBITDA was $54.4 million. The company raised FY2026 guidance to $80-$110 million adjusted EBITDA and $1.5-$1.6 billion revenue.

rttnews.com6 min

AUG 10

$PIIIHigh

P3 Health Partners Inc. (PIII): Results of Operations and Financial Condition

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ:

SEC EDGAR 8-K6 min

MAY 31

$PIIIMedAI 8/10

Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3%

P3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.

dailypolitical.com4 min

MAY 28

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).